PMID- 38291069
OWN - NLM
STAT- MEDLINE
DCOM- 20240208
LR  - 20240208
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 14
IP  - 1
DP  - 2024 Jan 30
TI  - Efficacy and safety of intravitreal faricimab for neovascular age-related macular 
      degeneration: a systematic review and meta-analysis.
PG  - 2485
LID - 10.1038/s41598-024-52942-3 [doi]
LID - 2485
AB  - We conducted a systematic review and meta-analysis to evaluate the visual, 
      anatomical, and safety outcomes of the intravitreal faricimab, a novel vascular 
      endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2) bispecific agent, in 
      neovascular age-related macular degeneration (nAMD) patients. The follow-up times 
      in the included studies ranged from a minimum of 36 weeks to a maximum of 
      52 weeks. EMBASE, Ovid-Medline, Cochrane Central Register of Controlled Trials 
      (CENTRAL), Web of Science, Scopus, the WHO ICTRP, ClinicalTrial.gov, the EU 
      Clinical Trials Register, and Chinese Clinical Trial Registry (ChiCTR) were 
      searched (The last literature search was performed on August 17, 2023) for 
      randomized controlled trials (RCTs) comparing faricimab with control groups for 
      neovascular age-related macular degeneration (nAMD). The risk of bias for 
      eligible RCTs was independently assessed using the Cochrane Risk of Bias Tool by 
      two authors (W.-T.Y. and C.-S.W.). The meta-analysis was conducted using Review 
      Manager 5.4 software. The mean best corrected visual acuity (BCVA), central 
      subfield thickness (CST), total choroidal neovascularization (CNV) area, and 
      total lesion leakage were analyzed as continuous variables and the outcome 
      measurements were reported as the weighted mean difference (WMD) with a 95% 
      confidence interval (CI). The ocular adverse events and ocular serious adverse 
      events were analyzed as dichotomous variables and the outcome measurements were 
      analyzed as the odds ratios (ORs) with a 95% CI. Random-effects model was used in 
      our study for all outcome synthesizing due to different clinical characteristics. 
      Four RCTs with 1,486 patients were eligible for quantitative analysis. There was 
      no statistically significant difference between intravitreal faricimab and 
      anti-VEGF in BCVA [weighted mean difference (WMD) = 0.47; 95% CI: (- 0.17, 
      1.11)]. The intravitreal faricimab group showed numerically lower CST 
      [WMD =  - 5.96; 95% CI = (- 7.11, - 4.82)], total CNV area [WMD =  - 0.49; 95% 
      CI = (- 0.68, - 0.30)], and total lesion leakage [WMD =  - 0.88; 95% 
      CI = (- 1.08, - 0.69)] after intravitreal therapy compared with the intravitreal 
      anti-VEGF group. There were no statistically significant differences between 
      intravitreal faricimab and anti-VEGF in ocular adverse events (AEs) [pooled odds 
      ratio (OR) = 1.10; 95% CI = (0.81, 1.49)] and serious adverse events (SAEs) 
      [pooled OR = 0.84; 95% CI = (0.37, 1.90)]. The intravitreal bispecific 
      anti-VEGF/angiopoietin 2 (Ang2) antibody faricimab with a extended injection 
      interval was non-inferior to first-line anti-VEGF agents in BCVA. It was safe and 
      had better anatomical recovery. Large, well-designed RCTs are needed to explore 
      the potential benefit of extended faricimab for nAMD. This systematic review was 
      registered in the International Prospective Register of Systematic Reviews 
      (PROSPERO) database (CRD42022327450).
CI  - (c) 2024. The Author(s).
FAU - Yen, Wei-Ting
AU  - Yen WT
AUID- ORCID: 0000-0002-1473-2531
AD  - Department of Ophthalmology, Tri-Service General Hospital, National Defense 
      Medical Center, Taipei, Taiwan.
FAU - Wu, Chen-Shu
AU  - Wu CS
AD  - Department of Internal Medicine, Tri-Service General Hospital, National Defense 
      Medical Center, Taipei, Taiwan.
FAU - Yang, Chang-Hao
AU  - Yang CH
AD  - Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
AD  - Department of Ophthalmology, National Taiwan University College of Medicine, 
      Taipei, Taiwan.
FAU - Chen, Yi-Hao
AU  - Chen YH
AD  - Department of Ophthalmology, Tri-Service General Hospital, National Defense 
      Medical Center, Taipei, Taiwan.
FAU - Lee, Cho-Hao
AU  - Lee CH
AUID- ORCID: 0000-0002-6061-5168
AD  - Division of Hematology and Oncology Medicine, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, 
      Chenggong Rd., Neihu Dist., Taipei City, 114, Taiwan. drleechohao@gmail.com.
FAU - Hsu, Cherng-Ru
AU  - Hsu CR
AUID- ORCID: 0000-0002-4390-0389
AD  - Department of Ophthalmology, Show Chwan Memorial Hospital, No. 542, Sec. 1, 
      Zhongshan Rd., Changhua City, 500, Changhua County, Taiwan. 
      josephinesheu@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20240130
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (faricimab)
SB  - IM
MH  - Humans
MH  - Angiogenesis Inhibitors/adverse effects
MH  - *Antibodies, Bispecific/adverse effects
MH  - Intravitreal Injections
MH  - *Macular Degeneration/drug therapy
PMC - PMC10827713
COIS- The authors declare no competing interests.
EDAT- 2024/01/31 00:42
MHDA- 2024/02/01 06:42
PMCR- 2024/01/30
CRDT- 2024/01/30 23:18
PHST- 2023/02/13 00:00 [received]
PHST- 2024/01/25 00:00 [accepted]
PHST- 2024/02/01 06:42 [medline]
PHST- 2024/01/31 00:42 [pubmed]
PHST- 2024/01/30 23:18 [entrez]
PHST- 2024/01/30 00:00 [pmc-release]
AID - 10.1038/s41598-024-52942-3 [pii]
AID - 52942 [pii]
AID - 10.1038/s41598-024-52942-3 [doi]
PST - epublish
SO  - Sci Rep. 2024 Jan 30;14(1):2485. doi: 10.1038/s41598-024-52942-3.